Aridis Pharmaceuticals Inc
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin… Read more
Aridis Pharmaceuticals Inc (ARDS) - Net Assets
Latest net assets as of September 2023: $-11.80 Million USD
Based on the latest financial reports, Aridis Pharmaceuticals Inc (ARDS) has net assets worth $-11.80 Million USD as of September 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.53 Million) and total liabilities ($18.34 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-11.80 Million |
| % of Total Assets | -180.62% |
| Annual Growth Rate | N/A |
| 5-Year Change | -192.09% |
| 10-Year Change | N/A |
| Growth Volatility | 169.62 |
Aridis Pharmaceuticals Inc - Net Assets Trend (2015–2022)
This chart illustrates how Aridis Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Aridis Pharmaceuticals Inc (2015–2022)
The table below shows the annual net assets of Aridis Pharmaceuticals Inc from 2015 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-24.23 Million | -71.74% |
| 2021-12-31 | $-14.11 Million | -62.54% |
| 2020-12-31 | $-8.68 Million | -338.75% |
| 2019-12-31 | $3.64 Million | -86.18% |
| 2018-12-31 | $26.31 Million | +130.10% |
| 2017-12-31 | $11.44 Million | -16.98% |
| 2016-12-31 | $13.78 Million | +780.92% |
| 2015-12-31 | $-2.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aridis Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18437600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | % |
| Other Comprehensive Income | $5.05 Million | % |
| Other Components | $166.38 Million | % |
| Total Equity | $-24.23 Million | 100.00% |
Aridis Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Aridis Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wen Acquisition Corp Warrant
NASDAQ:WENNW
|
$3.85K |
|
TOTALENERGIES MARKETING NIGERIA PLC
XNSA:TOTAL
|
$3.85K |
|
CAP LEASE AVIATION
LSE:CLA
|
$3.85K |
|
COMPAGNIE IMMOBILI
SEM:CIMO
|
$3.86K |
|
INCITY IMMOB - Dusseldorf Stock Exchang
DU:IC8
|
$3.84K |
|
EAM SOL
BE:EA2
|
$3.84K |
|
A-Frontier Co. Ltd.
KO:036180
|
$3.84K |
|
Ceylon Cold Stores PLC
CM:CCSN0000
|
$3.83K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aridis Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -13,110,000 to -24,232,000, a change of -11,122,000.
- Net loss of 30,749,000 reduced equity.
- New share issuances of 12,609,000 increased equity.
- Other comprehensive income increased equity by 5,051,000.
- Other factors increased equity by 1,967,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-30.75 Million | -126.89% |
| Share Issuances | $12.61 Million | +52.03% |
| Other Comprehensive Income | $5.05 Million | +20.84% |
| Other Changes | $1.97 Million | +8.12% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Aridis Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $1.75 | $0.00 | x |
| 2017-12-31 | $1.45 | $0.00 | x |
| 2018-12-31 | $8.36 | $0.00 | x |
| 2019-12-31 | $0.43 | $0.00 | x |
| 2020-12-31 | $-0.95 | $0.00 | x |
| 2021-12-31 | $-1.07 | $0.00 | x |
| 2022-12-31 | $-1.29 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aridis Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -159.74%
- • Asset Turnover: 1.31x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-144.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | -286.58% | 0.74x | 0.00x | $-8.00 Million |
| 2016 | -61.14% | -371.18% | 0.10x | 1.64x | $-9.80 Million |
| 2017 | -215.60% | -2866.98% | 0.03x | 2.32x | $-25.80 Million |
| 2018 | -84.00% | -801.78% | 0.09x | 1.20x | $-24.74 Million |
| 2019 | -797.19% | -2836.20% | 0.04x | 7.69x | $-29.35 Million |
| 2020 | 0.00% | -2233.30% | 0.07x | 0.00x | $-21.46 Million |
| 2021 | 0.00% | -2754.46% | 0.06x | 0.00x | $-40.97 Million |
| 2022 | 0.00% | -159.74% | 1.31x | 0.00x | $-28.33 Million |
Industry Comparison
This section compares Aridis Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aridis Pharmaceuticals Inc (ARDS) | $-11.80 Million | 0.00% | N/A | $3.84K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |